HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

deoxypyridinoline

structure given in first source
Also Known As:
N-(5-amino-5-carboxypentyl)-3-hydroxy-4-(2-amino-2-carboxyethyl)-5-(3-amino-3-carboxypropyl)pyridine; deoxypyridinoline, stereoisomer; lysylpyridinoline; Pyridinium, 4-(2-amino-2-carboxyethyl)-1-(5-amino-5-carboxypentyl)-3-(3-amino-3-carboxypropyl)-5-hydroxy-, hydroxide, inner salt, stereoisomer
Networked: 765 relevant articles (20 outcomes, 77 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Nishizawa, Yoshiki: 9 articles (04/2006 - 10/2002)
2. Inaba, Masaaki: 8 articles (04/2006 - 10/2002)
3. Ishimura, Eiji: 8 articles (04/2006 - 10/2002)
4. Delmas, P D: 8 articles (01/2005 - 01/2000)
5. Fraser, W D: 7 articles (12/2012 - 09/2000)
6. Coxam, V: 6 articles (07/2008 - 11/2000)
7. Okuno, Senji: 6 articles (02/2006 - 10/2002)
8. Garnero, P: 6 articles (01/2005 - 02/2000)
9. Lucas, Edralin A: 5 articles (01/2011 - 02/2002)
10. Arjmandi, Bahram H: 5 articles (01/2011 - 02/2002)

Related Diseases

1. Bone Resorption
2. Prostatic Neoplasms (Prostate Cancer)
3. Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
07/01/1997 - "Urinary levels (mean +/- SD) of deoxypyridinoline were measured by a competitive immunoassay, and serum levels of P1CP and 1CTP were measured by radioimmunoassay in 30 patients with benign prostatic hyperplasia, 18 patients with prostatic carcinoma without bone metastases, and 27 patients with prostatic carcinoma and bone metastases. "
08/01/1998 - "Levels of urinary pyridinoline and deoxypyridinoline in urine in patients with bony metastatic prostate cancer were significantly greater than levels in patients with benign prostatic hyperplasia or localized prostate cancer. "
04/01/1994 - "Urinary excretion of pyridinoline and deoxypyridinoline was significantly greater in patients with metastatic carcinoma of the prostate compared with patients with either benign prostatic hyperplasia (Mann-Whitney-Wilcoxon rank sum analysis, p < 0.00004 and 0.002, respectively) or localized prostate cancer (Mann-Whitney-Wilcoxon, p < 0.00001 and 0.00005, respectively). "
08/01/1998 - "Urinary pyridinoline and deoxypyridinoline were measured in patients with benign prostatic hyperplasia, clinically localized prostate cancer and prostate cancer with bone metastases. "
07/01/1997 - "Urinary concentrations of deoxypyridinoline (pmol/micromol creatinine) in patients with prostatic carcinoma and bone metastases (10.4 +/- 7.7) were significantly higher than those in similar patients without bone metastases (4.3 +/- 1.3) and those in patients with benign prostatic hyperplasia (3.8 +/- 1.2). "
4. Osteoporosis
5. Neoplasm Metastasis (Metastasis)

Related Drugs and Biologics

1. pyridinoline
2. Osteocalcin
3. Alkaline Phosphatase
4. Biological Markers (Surrogate Marker)
5. Collagen Type I (Type I Collagen)
6. collagen type I trimeric cross-linked peptide
7. Calcium
8. Hydroxyproline (4 Hydroxyproline)
9. risedronic acid (risedronate)
10. Etidronic Acid (HEDP)

Related Therapies and Procedures

1. Hormone Replacement Therapy (Therapy, Hormone Replacement)
2. Transplants (Transplant)
3. Continuous Ambulatory Peritoneal Dialysis (CAPD)
4. Arthroplasty
5. Ovariectomy (Oophorectomy)